Takuya Toyonaga1, Levi M Smith2,3, Sjoerd J Finnema4, Jean-Dominique Gallezot4, Mika Naganawa4, Jason Bini4, Tim Mulnix4, Zhengxin Cai4, Jim Ropchan4, Yiyun Huang4, Stephen M Strittmatter3,5, Richard E Carson4. 1. PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut takuya.toyonaga@yale.edu. 2. Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut. 3. Program in Cellular Neuroscience, Neurodegeneration, and Repair, Yale University School of Medicine, New Haven, Connecticut; and. 4. PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut. 5. Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.
Abstract
11C-UCB-J is a new PET tracer for synaptic density imaging. Recently, we conducted 11C-UCB-J PET on patients with mild cognitive impairment or early Alzheimer disease (AD) and found a 41% decrease in specific binding in the hippocampus compared with healthy subjects. We hypothesized that 11C-UCB-J may have potential to be a general biomarker for evaluating AD treatment effects via monitoring of synaptic density changes. In this study, we performed longitudinal 11C-UCB-J PET on AD mice to measure the treatment effects of saracatinib, which previously demonstrated synaptic changes with postmortem methods. Methods: Nine wild-type (WT) mice and 9 amyloid precursor protein and presenilin 1 double-transgenic (APPswe/PS1ΔE9 [APP/PS1]) mice underwent 3 11C-UCB-J PET measurements: at baseline, after treatment, and during drug washout. After baseline measurements, saracatinib, a Fyn kinase inhibitor currently in clinical development for AD treatment, was administered by oral gavage for 41 ± 11 d. Treatment-phase measurements were performed on the last day of treatment, and washout-phase measurements occurred more than 27 d after the end of treatment. SUVs from 30 to 60 min after injection of 11C-UCB-J were calculated and normalized by the whole-brain (WB) or brain stem (BS) average values as SUV ratio (SUVR(WB) or SUVR-1(BS)). Results: Hippocampal SUVR(WB) at baseline was significantly lower in APP/PS1 than WT mice (APP/PS1: 1.11 ± 0.04, WT: 1.15 ± 0.02, P = 0.033, unpaired t test). Using SUVR-1(BS) in the hippocampus, there was also a significant difference at baseline (APP/PS1: 0.48 ± 0.13, WT: 0.65 ± 0.10, P = 0.017, unpaired t test). After treatment with saracatinib, hippocampal SUVR(WB) in APP/PS1 mice was significantly increased (P = 0.037, paired t test). A trend-level treatment effect was seen with hippocampal SUVR-1(BS). Saracatinib treatment effects may persist, as there were no significant differences between WT and APP/PS1 mice after drug washout. Conclusion: On the basis of the 11C-UCB-J PET results, hippocampal synaptic density was lower in APP/PS1 mice than in WT mice at baseline, and this deficit was normalized by treatment with saracatinib. These results support the use of 11C-UCB-J PET to identify disease-specific synaptic deficits and to monitor treatment effects in AD.
11C-UCB-J is a new PET tracer for synaptic density imaging. Recently, we conducted 11C-UCB-J PET on patients with mild cognitive impairment or early Alzheimer disease (AD) and found a 41% decrease in specific binding in the hippocampus compared with healthy subjects. We hypothesized that 11C-UCB-J may have potential to be a general biomarker for evaluating AD treatment effects via monitoring of synaptic density changes. In this study, we performed longitudinal 11C-UCB-J PET on AD mice to measure the treatment effects of saracatinib, which previously demonstrated synaptic changes with postmortem methods. Methods: Nine wild-type (WT) mice and 9 amyloid precursor protein and presenilin 1 double-transgenic (APPswe/PS1ΔE9 [APP/PS1]) mice underwent 3 11C-UCB-J PET measurements: at baseline, after treatment, and during drug washout. After baseline measurements, saracatinib, a Fyn kinase inhibitor currently in clinical development for AD treatment, was administered by oral gavage for 41 ± 11 d. Treatment-phase measurements were performed on the last day of treatment, and washout-phase measurements occurred more than 27 d after the end of treatment. SUVs from 30 to 60 min after injection of 11C-UCB-J were calculated and normalized by the whole-brain (WB) or brain stem (BS) average values as SUV ratio (SUVR(WB) or SUVR-1(BS)). Results: Hippocampal SUVR(WB) at baseline was significantly lower in APP/PS1 than WT mice (APP/PS1: 1.11 ± 0.04, WT: 1.15 ± 0.02, P = 0.033, unpaired t test). Using SUVR-1(BS) in the hippocampus, there was also a significant difference at baseline (APP/PS1: 0.48 ± 0.13, WT: 0.65 ± 0.10, P = 0.017, unpaired t test). After treatment with saracatinib, hippocampal SUVR(WB) in APP/PS1mice was significantly increased (P = 0.037, paired t test). A trend-level treatment effect was seen with hippocampal SUVR-1(BS). Saracatinib treatment effects may persist, as there were no significant differences between WT and APP/PS1mice after drug washout. Conclusion: On the basis of the 11C-UCB-J PET results, hippocampal synaptic density was lower in APP/PS1mice than in WT mice at baseline, and this deficit was normalized by treatment with saracatinib. These results support the use of 11C-UCB-J PET to identify disease-specific synaptic deficits and to monitor treatment effects in AD.
Authors: Songye Li; Zhengxin Cai; Xiaoai Wu; Daniel Holden; Richard Pracitto; Michael Kapinos; Hong Gao; David Labaree; Nabeel Nabulsi; Richard E Carson; Yiyun Huang Journal: ACS Chem Neurosci Date: 2018-11-16 Impact factor: 4.418
Authors: Y Ma; P R Hof; S C Grant; S J Blackband; R Bennett; L Slatest; M D McGuigan; H Benveniste Journal: Neuroscience Date: 2005-09-13 Impact factor: 3.590
Authors: Martine M Mirrione; Wynne K Schiffer; Joanna S Fowler; Dave L Alexoff; Stephen L Dewey; Stella E Tsirka Journal: Neuroimage Date: 2007-07-18 Impact factor: 6.556
Authors: Megan Larson; Mathew A Sherman; Fatou Amar; Mario Nuvolone; Julie A Schneider; David A Bennett; Adriano Aguzzi; Sylvain E Lesné Journal: J Neurosci Date: 2012-11-21 Impact factor: 6.167
Authors: Ji Won Um; Haakon B Nygaard; Jacqueline K Heiss; Mikhail A Kostylev; Massimiliano Stagi; Alexander Vortmeyer; Thomas Wisniewski; Erik C Gunther; Stephen M Strittmatter Journal: Nat Neurosci Date: 2012-07-22 Impact factor: 24.884
Authors: Erik C Gunther; Levi M Smith; Mikhail A Kostylev; Timothy O Cox; Adam C Kaufman; Suho Lee; Ewa Folta-Stogniew; George D Maynard; Ji Won Um; Massimiliano Stagi; Jacqueline K Heiss; Austin Stoner; Geoff P Noble; Hideyuki Takahashi; Laura T Haas; John S Schneekloth; Janie Merkel; Christopher Teran; Zahra K Naderi; Surachai Supattapone; Stephen M Strittmatter Journal: Cell Rep Date: 2019-01-29 Impact factor: 9.423
Authors: Joshua Spurrier; LaShae Nicholson; Xiaotian T Fang; Austin J Stoner; Takuya Toyonaga; Daniel Holden; Timothy R Siegert; William Laird; Mary Alice Allnutt; Marius Chiasseu; A Harrison Brody; Hideyuki Takahashi; Sarah Helena Nies; Azucena Pérez-Cañamás; Pragalath Sadasivam; Supum Lee; Songye Li; Le Zhang; Yiyun H Huang; Richard E Carson; Zhengxin Cai; Stephen M Strittmatter Journal: Sci Transl Med Date: 2022-06-01 Impact factor: 19.319
Authors: Daniele Bertoglio; Nicolas Halloin; Stef De Lombaerde; Aleksandar Jankovski; Jeroen Verhaeghe; Charles Nicaise; Steven Staelens Journal: J Nucl Med Date: 2022-01-13 Impact factor: 11.082
Authors: Majken B Thomsen; Jan Jacobsen; Thea P Lillethorup; Anna C Schacht; Mette Simonsen; Marina Romero-Ramos; David J Brooks; Anne M Landau Journal: J Cereb Blood Flow Metab Date: 2020-06-14 Impact factor: 6.200
Authors: Negin Holland; P Simon Jones; George Savulich; Julie K Wiggins; Young T Hong; Tim D Fryer; Roido Manavaki; Selena Milicevic Sephton; Istvan Boros; Maura Malpetti; Frank H Hezemans; Franklin I Aigbirhio; Jonathan P Coles; John O'Brien; James B Rowe Journal: Mov Disord Date: 2020-07-11 Impact factor: 9.698